Legacy recruits heavily to meet growing steriles demand
Company to reach 250 employees by year end to meet growing drug product manufacturing demand.
Legacy Pharmaceuticals it aims to increase headcount to 250 employees by year end to respond to the increasing demand in one-stop-shop drug products manufacturing services, as well as investing in its current assets.
Mike Danzi, Legacy CEO comments: “Being based in Basel we are fortunate to be able draw from a pool of highly educated and motivated staff - the region has in excess of 900 pharma and medtech companies employing over 50,000 people. This combination of motivation, skill and experience is key to successful project transfer success and will ensure we can support both present and future customers in their drive to succeed in the increasingly competitive biologics market.”
Legacy has been recruiting steadily during the year, enabling a move to third shifts in both semi solids and steriles, the restructuring of the engineering department, additional QA/validation/qualification resources and the expansion of the IT organisation.
“New employees tell us they value our breadth of products and the opportunities they have for further professional development. We actively encourage ownership of projects and creativity, while trying to foster a friendly supportive family environment. Because in the final analysis, spending money on new equipment and capacity means nothing if you do not have the right people to run it,” concludes Danzi.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance